News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the United States Patent and Trademark Office for its cell therapy technology. The cell sorting patent will be protected until July 2038 for the company's innovative cell selection and enrichment technology. This patent covers the production of IsletRx, the company's product for the treatment and potential cure for diabetes. The company's technology is unique with its ability to select and enrich only the highest functioning and purest islet cells from the population of pluripotent stem cells which enables the maximum therapeutic effect. The approval of this patent in the USA is particularly important, especially in light of our collaboration project with iTolerance, an American company in the diabetes field and the BIRD Foundation. The project will combine Kadimastem’s and iTolerance’s technologies to develop and commercialize a breakthrough regenerative technology to cure diabetes without the need for life-threatening chronic immuno-suppression. The project will receive a 3.5 million NIS (US $1Million) grant from the BIRD Foundation for this project. In addition, the importance of unloading the social and financial burden of type 1 diabetes in the United States currently is crucial now more than ever. Approximately 1.45 million Americans are living with T1D, which accounts for about 3.75% of all diagnosed cases of diabetes[1]. According to a new study (2020) published in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), people who live with Type 1 Diabetes (T1D) in the United States right now, as well as those who will develop the disease over the next 10 years, will pay a collective $813 billion over their lifetimes in medical costs and in lost income and productivity costs, as compared to a similar group that does not have T1D[2]. Insulin-dependent type two diabetics which outnumber the number of T1D patients will similarly benefit from this treatment. Asaf Shiloni, company CEO: “Kadimastem highly believes that the company’s treatment can improve the quality of lives for hundreds of thousands of those dealing with the daily struggles of insulin dependent diabetes (IDD) by presenting a potential cure for IDD with our unique patented solution with IsletRx cells. In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article [3] in Frontiers in Endocrinology. About IsletRx The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes. [1] https://diabetesresearch.org/diabetes-statistics/#:~:text=37.3%20million%20people%2C%20or%2011.3,%2C%20economic%2C%20and%20ethnic%20backgrounds. [2] https://www.jdrf.org/blog/2020/02/24/new-jdrf-funded-study-finds-lifetime-t1d-management-costs-a-collective-813-billion/ [3] https://www.frontiersin.org/articles/10.3389/fendo.2021.635405/full At Kadimastem we envision being a global leader in cell therapy.Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

June 20, 2023 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Accessible Science And Collaboration Are Critical Factors For Advancing Sustainable Development Goals, Global Academic Leaders Concurred

Elsevier

Joint seminar organized by the Ministry of Education and Elsevier ahead of the 4th G20 Education Working Group meeting highlights India’s potential and role as a centre of research excellence According to data from Elsevier – a global leader in evidence-based clinical practice content, research publishing and information analytics – India’s scholarly output has been steadily increasing, with a Compound Annual Growth Rate of around 11% over the past 20 years and has also now moved to becoming the third largest producer of scientific research, overtaking the UK in 2022. The country also boasts achievements in academic quality where its Field Weighted Citation Impact (an international measure of research quality) has improved from 0.85 in 2019 to 1.05 in 2021, putting India above the global average for publication citations. In addition, the Indian government’s focus on driving qualitative research to strengthen the country's competitiveness in global research and innovation has resulted in India achieving its 40th ranking in WIPO’s Global Innovation Index 2022. These were amongst some of India’s academic achievements that were spotlighted at a seminar jointly organized by India’s Ministry of Education in partnership with Elsevier as a precursor discussion to the 4th G20 Education Working Group meeting around the topic of “Accessible science: fostering collaboration” which took place on 16 June 2023. The seminar convened stakeholders from the G20 group of nations across the scientific community to discuss best practices for accessible science, how accessible science can be applied across individual nations with differing local capacities, and ways to utilize science practices to support global progress. Hon’ble MoS Shri Dr. Subhas Sarkar, Ministry of Education, while inaugurating the event, stated: “Guided by inclusivity and innovation, we seek to strengthen ties with higher education institutions worldwide. Through robust partnerships, joint research endeavors, and shared knowledge, we aspire to create a vibrant ecosystem that transcends borders. India's G20 Presidency recognizes the importance of accessible science in addressing global challenges and fostering sustainable development. Openness, transparency, and inclusivity are crucial to trust and integrity in scientific approaches. By embracing Open Science, we can ensure data sharing, research reproducibility, and robust societal impacts. Together through partnerships, we will navigate uncharted waters and create a brighter future for all through scientific innovation.” During his keynote address, Shri K. Sanjay Murthy, Secretary Higher Education, Ministry of Education, GOI, said: “Cooperation and an exchange of knowledge are key to build a thriving ecosystem that cuts across national boundaries and addresses global challenges. We understand that there is a need to enhance our research output and hence seek pathways to foster collaborations among universities and academic institutions. Let us strive to provide solutions for global challenges and achieve our sustainable development goals, leaving a visible impact on the richness of our collaborative endeavours.” “India’s stellar performance in scientific research is intrinsically tied to the local and global trends that we have seen towards accessible science,” said Dr. Nick Fowler, Chief Academic Officer at Elsevier and Chair of The International Association of STM Publishers, which represents over 140 global academic publishers. “As scientific findings become more accessible, other researchers around the world can use and build on the findings, thereby enhancing academic quality.” Dr. Fowler added: “Academic papers developed via international collaborations in India have been cited twice as often as those with no international collaboration, and India would do well in optimizing opportunities to expand its global collaborations, particularly with G20 countries.” At the seminar, highlights from an exclusive Elsevier report commissioned by The Ministry of Education, Fostering collaboration: a study of scientific publications with authors in G20 countries, was also presented by the report’s author, Dr. Carlos Henrique de Brito Cruz, Senior Vice President at Elsevier and Professor Emeritus, State University of Campinas. "The research landscape in the world is changing. Thirty years ago, it was the rich countries of the Global North that conducted research. Now, there is a change, and countries from the Global South are becoming more and more relevant in research and science,” said Dr. de Brito Cruz. “India has brought so many collaborations and one of the best things they’re doing in the growth of scientific production is Sustainable Development Goal #2, which is related to reducing hunger in the world, where the scientific production of India is going up 25 percent a year. Soon, India will have a mass of knowledge that will become a reference for every other country in the world." For the main discussion session, several esteemed panelists joined us and shared their insights on ways to foster collaboration between G20 countries through accessible multi-lingual regional resources and multi-lateral open facilities; and various approaches to enhance academic interactions to meet UN SDGs. Panelists at the session included Prof. S. K. Satheesh (IISc Bengaluru and Chief Editor of Current Science (Indian Academy of Sciences); Mr. Piers Purdy (Head of G20, Research and Innovation); Mr. Kaspar Meyer (Head of S&T, German Embassy in India; Mr. Carlos Henrique de Brito Cruz (SVP, Research Networks, Elsevier, Professor Emeritus, of Campinas, Unicamp, Brazil); Prof. Amit Agarwal (Dean, International Relations, IIT Bombay); Mr. Mudit Narain (Formerly Program Director at the Atal Innovation Mission, NITI Aayog and Director, Foundation for Advancing S&T); and Dr. Ravindra Utgikar (Vice President Corporate Strategy & Marketing at Praj Industries Ltd, Pune). This session was chaired by Prof. Sunil S Bhagwat (Director, IISER Pune) and Co-chaired by Dr Ayesha Chaudhary (Advisor, Stanford University, Stanford Byers Center for Bio-design, India program; Consultant, World Bank and Adjunct Faculty, IIT Jodhpur). A panel discussion moderated by Dr. Nagaraj Balasubramanian (Associate Professor, IISER Pune) with the above participants was held where aspects related to growth in capacity in terms of infrastructure and human resource were discussed along with inputs from the audience. The importance of interactions among researchers at the global level and various models to achieve this was discussed in this session. --- About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Elsevier in India As a trusted partner in India, Elsevier delivers verified research content, innovative localized digital solutions and valuable analytics to enhance and amplify Indian research to benefit society and contribute to the global and local canon of scholarly articles. In healthcare, we help medical, clinical and nursing students transition from classroom learnings to clinical settings. Since 1996, Elsevier has supported and progressed alongside India in the nation’s pursuit of scientific and healthcare excellence. We’ve helped Indian academic, corporate and medical researchers gain access to and publish quality research, supporting the amplification of their scientific achievements globally. We’ve also participated in strategic national projects to improve the well-being of underserved populations. As an academic publisher, we’re proud of our pioneering efforts in helping to establish a robust foundation of scientific and medical research in India, contributing to its status as one of the world’s leading research nations. Having evolved from our roots in publishing, we’re now delivering a comprehensive portfolio of digital platforms and solutions that responds to the needs of academics and healthcare professionals throughout the country. Contact Details Elsevier Communications, UK Srishti Sharma +91 98999 54186 srishti@onpurposeconsulting.in Elsevier Jason Chan +65 6349 0240 j.chan@elsevier.com Company Website https://www.elsevier.com/

June 20, 2023 05:17 AM Eastern Daylight Time

Article thumbnail News Release

Xeris Pharmaceuticals shares latest product and partnership updates

Xeris Biopharma Holdings

Xeris Pharmaceuticals chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product line performance. Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a proven therapy for primary periodic paralysis; and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol and XeriJect, to support long-term product development and commercial success. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

June 19, 2023 12:58 PM Eastern Daylight Time

Video
Article thumbnail News Release

Doceree launches industry-first HCP-focused global DSP for media agencies at Cannes Lions 2023

Doceree Inc

Doceree, a leading global platform building unprecedented solutions for healthcare professionals (HCPs) through programmatic messaging with proprietary data tools, today announced the launch of Doceree Enterprise, an industry-first, HCP-focussed global Demand Side Platform (DSP), delivering an integrated ecosystem to media agencies with high-impact, built for scale programmatic capabilities to serve healthcare and life sciences brands. Doceree Enterprise, powered by proprietary HCP identity-resolution technology Espyian TM, is a fully self-serve ecosystem, enabling agencies to run highly targeted global and integrated campaigns with transparent and measurable outcomes. In addition to providing media agencies the access to worldwide web inventory through its SSP integrations, it also provides them ‘preferred access’ to Doceree’s specialized supply side platform (SSP) – the world’s largest integrated global network of 650+ endemic and point-of-care platforms, with a worldwide unique physician reach of over 2 million. On top of it, the agencies can bring their audience, data partners, and measurement tools to build their own healthcare-specific marketing platform. Agencies currently counter multiple challenges while buying media directly from third party publishers or from existing DSPs, which mostly have restricted presence in the US and experience compliance issues around regulations for advertising to HCPs outside of the US. The non-HCP media impacts the return on investments (ROI) of life sciences brands that are looking to engage prescribers through effective programmatic campaigns. Doceree has been relentlessly working to identify issues facing the pharma messaging ecosystem and close the gaps through its AI-enabled category-centric technologies that can precisely target HCPs and enable marketers to activate high-performing campaigns. “We are thrilled to launch our new DSP that creates unprecedented HCP personalization and customization for media agencies. The platform offers full suite of capabilities to media agencies to activate HCP-focused campaigns with utmost ease and convenience without worrying about transparency, performance or regulatory compliances,” said Harshit Jain MD, Founder & Global CEO, Doceree. “Doceree Enterprise will introduce never-seen before advancements in the category that will revolutionize HCP messaging. We will continue building category-first solutions that our partners would immensely benefit from.” The integrated ecosystem equips agencies with the ability to forecast campaigns; build HCP-only audiences & cohorts; activate, optimize and analyse campaigns to create omnichannel experiences; and measure campaign outcomes in near real time. “The rapidly evolving digital healthcare industry create new opportunities for marketing, engaging and educating HCPs. Doceree Enterprise is exactly the solution agencies are looking for to stand out from the competition on a global level. There is no ‘one solution fits all’ and the DSP uniquely addresses the gaps, curating an agency-specific platform that aligns with each agency’s specific needs. This first-of-its-kind approach to engaging HCPs is exciting and offers plenty of opportunities for agencies to run successful and scalable HCP campaigns for their healthcare clients,” said Jeffrey D. Erb, Chief Media Officer, Fishawack Health. Features of Doceree Enterprise giving it a competitive edge: The only true personalized ad-martech solution for HCP marketing Competitive edge through custom build features and tools developed collaboratively Multi-tenant solution with the ability to run multiple campaigns across markets Robust measurement capabilities, aiming to tie marketing efforts to business and clinical outcomes quantitatively Access to top-to-bottom HCP marketing funnel, including healthcare-centric inventory spanning endemic and point-of-care platforms Access global supply partnership or integrate a supply partner of your choice Doceree Enterprise is available for media agencies across the globe. About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Doceree Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Company Website https://doceree.com/us/

June 19, 2023 06:36 AM Eastern Daylight Time

Image
Article thumbnail News Release

Revolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solution

VistaGen Therapeutics Inc

Vistagen Therapeutics CEO Shawn Singh joined Steve Darling from Proactive to share news about the company that is a late-stage biopharmaceutical company based in South San Francisco, focusing on transforming the treatment options for anxiety disorders, depression disorders, and other neurological disorders. The company has developed a new class of drugs called "pherines" that are administered as nasal sprays. These drugs target specific receptors in the nose that connect to parts of the brain associated with mood disorders. Singh telling Proactive its lead drug, fasedienol or PH94B, has received FDA Fast Track designation for social anxiety disorder. The company has several other assets in their pipeline and plans to advance them through phase 3 programs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 16, 2023 12:36 PM Eastern Daylight Time

Video
Article thumbnail News Release

Roquefort Therapeutics returns to the market with new study data

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after the biotech company announced that it had achieved 'significant results' in laboratory studies involving its anti-cancer mRNA treatment. Reginald reveals more information about the study and addresses the return of Roquefort shares to the market after a delayed audit prompted a temporary suspension. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 16, 2023 06:10 AM Eastern Daylight Time

Video
Article thumbnail News Release

Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO

Ensysce Biosciences

Ensysce Bioscience CEO Dr Lynn Kirkpatrick joined Steve Darling from Proactive to share more details about the company that has proprietary technology platforms with the hopes of safer prescription drugs. The company does that through its Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. The key is the drug can only be activated or turned on when it is swallowed and comes into contact with the natural digestive enzyme trypsin, which is found in the small intestine. Kirkpatrick telling Proactive more about the platforms and also about its clinical trials which have shown promising results. Ensysce also plans to initiate a phase 3 trial and seek FDA approval. The company's goal is to address the opioid crisis by offering effective pain relief while minimizing the risk of addiction and abuse. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 15, 2023 01:34 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioVie research and social impact initiatives recognize Alzheimer's & Brain Awareness Month

BioVie Inc

BioVie chief medical officer Dr Joseph Palumbo joins Natalie Stoberman from the Proactive newsroom to share the company's latest research and social impact on cognitive diseases to bring awareness to Alzheimer's & Brain Awareness Month. Palumbo says BioVie's latest research has shown improvements in motor behaviour for Parkinson's patients, reversing the "off state" experienced by some individuals. In addition, Palumbo explains there have also been observations of interesting effects on gene methylation and reversing stress-related changes in DNA. BioVie's research also focuses on the metabolic aspects of these diseases and their impact on cognition. The company has made social impact investments, including donations to organizations and partnering with universities for research initiatives. BioVie is dedicated to treating age-related diseases and expects to provide data from their studies by the end of the year. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 15, 2023 01:15 PM Eastern Daylight Time

Video
Article thumbnail News Release

Vivos Therapeutics highlights 1Q financial and operational growth with major acquisition

Vivos Therapeutics

Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studios to discuss the company's first-quarter financial and operational highlights. Huntsman says the main highlight of comes from acquisition of certain US and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics to fill gaps in Vivos' product line. Huntsman also shares how the company's cost reduction efforts, distribution agreements, and the potential for further growth have been executed while the company continues to reach more patients and providers. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

June 15, 2023 12:55 PM Eastern Daylight Time

Video
1 ... 9596979899 ... 250
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.